Wu Jingsong

Studied under DR. Zhou Liangfu and Dr. Chen Xiancheng. Deputy Director of Neurosurgery at Huashan Hospital, Fudan University; Director of the Glioma Center at Huashan Hospital; Deputy Director of the Neurosurgery Institute at Fudan University; Director of the Brain Function Laboratory; Head of the iMRI Digital Integrated Neurosurgical Center; Director of the Shanghai Key Laboratory for Clinical Trials and Translation of Brain-Computer Interfaces. Recipient of the Shanghai Municipal Health System Outstanding Academic Leader (“New Hundred Talents Program”); Chairman of the Neuro-Oncology Professional Committee of the Shanghai Anti-Cancer Association; Head of the Glioma Professional Group at the National Center for Neurological Diseases. Successfully conducted China's first prospective clinical trial of an invasive brain-computer interface; established a molecular subtyping, AI imaging diagnosis, and molecular navigation system, reducing single-case analysis time from 12 minutes to 3 minutes and increasing accuracy from 78% to 93%. Specializes in treating neurological tumors such as gliomas, pituitary adenomas, craniopharyngiomas, meningiomas, and lymphomas. As project leader, has undertaken multiple research projects, including the “12th Five-Year Plan” National Science and Technology Support Program. Holds 3 authorized invention patents and 10 utility model patents. He has focused on precision neurosurgery and clinical translational research in brain tumors for nearly 30 years, leading and completing more than ten projects, including the National Science and Technology Support Program, the National Natural Science Foundation of China, the Shanghai Municipal Education Commission's Major Natural Science Project, and the Shanghai Municipal Science and Technology Commission's Key Basic Research Project; he has published more than 200 academic papers. He is the first Chinese doctor to summit Mount Everest. In 2025, his team reported a preclinical study in the *Journal of Cancer Immunotherapy* on the administration of neural stem cells via oncolytic viruses through the ventricle. In 2026, they revealed the mechanism of tumor "self-walling" driven by interleukin-8 in *Neuro-Oncology*.